Business
Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts focused on the company’s genomic tests for
About this update from Veracyte, Inc.
[{"type":"text","content":" SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nVeracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts focused on the company’s genomic tests for interstitial lung disease (Envisia Genomic Classifier) and lung cancer (Percepta Nasal Swab) will be presented at the American Thoracic Society (ATS) 2023 International Conference. The meeting will take place May 19-24 in Washington, D.C.\n\n\n“We look forward to these new data being shared at ATS 2023, which explore the impact of our Envisia Genomic Classifier on diagnosis and treatment decisions for patients with interstitial lung diseases, as well as in identifying patients whose ILD is likely to progress,” said Bill Bulman, M.D., Veracyte’s medical director for Pulmonology. “In addition, expanded preliminary data will be presented regarding use of the Percepta Nasal Swab test on potentially cancerous lung nodules found on CT scans.”\n\n\nThe following abstracts will be presented at the ATS 2023 International Conference:\n\n\nTitle: Genomic Classifier for Usual Interstitial Pneumonia Predicts Progression in Fibrotic Lung Disease Across a Range of Clinical Diagnoses\nPresenter: Ganesh Raghu, M.D., University of Washington\nSession: A102 – Poster 822\nFormat: Poster Discussion Session\nDate/Time: May 21, 2023, 2:15 p.m. - 4:15 p.m. ET\nLocation: Walter E. Washington Convention Center, Room 209 A-C (Level 2)\n\n\nTitle: The Impact of Genomic Classifier in Patients With Undiagnosed Interstitial Lung Disease\nPresenter: Diana Espinoza Barrera, M.D., Tulane University\nSession: C39 – Poster P555\nFormat: Thematic Poster Session\nDate/Time: May 23, 2023, 11:30 a.m. - 1:15 p.m. ET\nLocation: Walter E. Washington Convention Center, Area E, Hall C (Lower Level)\n\n\nTitle: Demonstrating Clinical Utility for a Nasal Genomic Classifier for Lung Nodules: Addressing the Clinical Trial Learning Curve With a Familiarization Phase\nPresenter: Farah Madhani-Lovely, M.D., Renown Health\nSession: D31 – Poster 317\nFormat: Poster Discussion Session\nDate/Time: May 24, 2023, 8:00 a.m. - 10:00 a.m. ET\nLocation: Walter E. Washington Convention Center, Room 144 A-C (Street Level)\n\n\nAbout Veracyte\n\n\nVeracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need t...